Published in Cell Death Dis on October 18, 2012
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ (2014) 1.32
Wnt activation promotes neuronal differentiation of glioblastoma. Cell Death Dis (2013) 1.08
Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer. Epigenetics (2014) 0.93
Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells. J Transl Med (2014) 0.89
Glioma Stem Cells: Signaling, Microenvironment, and Therapy. Stem Cells Int (2016) 0.88
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). Int J Oncol (2015) 0.87
microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. Cell Mol Neurobiol (2014) 0.86
The hypoxia-inducible miR-429 regulates hypoxia-inducible factor-1α expression in human endothelial cells through a negative feedback loop. FASEB J (2014) 0.85
Development of targeted therapies in treatment of glioblastoma. Cancer Biol Med (2015) 0.83
Bortezomib downregulates MGMT expression in T98G glioblastoma cells. Cell Mol Neurobiol (2013) 0.82
Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. Nat Cell Biol (2016) 0.82
BMPs as therapeutic targets and biomarkers in astrocytic glioma. Biomed Res Int (2014) 0.81
TRAF2 facilitates vaccinia virus replication by promoting rapid virus entry. J Virol (2014) 0.80
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. Invest New Drugs (2013) 0.79
Inhibition of PI3K Signalling Selectively Affects Medulloblastoma Cancer Stem Cells. Biomed Res Int (2015) 0.79
Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Mol Cancer (2015) 0.79
Biological and clinical implications of cancer stem cells in primary brain tumors. Front Oncol (2013) 0.78
BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells. Sci Rep (2016) 0.78
Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model. Eur J Nucl Med Mol Imaging (2015) 0.77
Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma. Oncotarget (2015) 0.77
Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models. Neuro Oncol (2014) 0.77
Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells. PLoS One (2015) 0.76
Cellular plasticity regulated cancer stem cell niche: a possible new mechanism of chemoresistance. Cancer Cell Microenviron (2015) 0.76
Annexin 2A sustains glioblastoma cell dissemination and proliferation. Oncotarget (2016) 0.75
The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation. Sci Rep (2016) 0.75
Cancer Stem Cells: Cellular Plasticity, Niche, and its Clinical Relevance. J Stem Cell Res Ther (2016) 0.75
HIF1α regulates glioma chemosensitivity through the transformation between differentiation and dedifferentiation in various oxygen levels. Sci Rep (2017) 0.75
A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 8.50
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature (2006) 7.69
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer (2007) 4.54
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell (2008) 3.87
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol (2007) 3.23
Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res (2008) 2.84
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain (2010) 2.49
Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci U S A (2002) 2.39
Hypoxia inducible factors in cancer stem cells. Br J Cancer (2010) 2.21
Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene. J Biol Chem (2001) 1.99
Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol (2011) 1.80
BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med (2003) 1.67
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol (2008) 1.57
Methylguanine methyltransferase testing in glioblastoma: when and how? J Clin Oncol (2007) 1.54
Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol (2009) 1.53
Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol (2006) 1.46
Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol (2007) 1.41
Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells (2010) 1.40
Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1alpha variant for local induction of angiogenesis. Proc Natl Acad Sci U S A (2006) 1.39
Oxygen tension controls the expansion of human CNS precursors and the generation of astrocytes and oligodendrocytes. Mol Cell Neurosci (2007) 1.38
Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets (2009) 1.32
Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res (2007) 1.31
Glioblastoma and stem cells. Neoplasma (2008) 1.23
Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain (2010) 1.23
Hypoxia and HIF1alpha repress the differentiative effects of BMPs in high-grade glioma. Stem Cells (2009) 1.22
The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery (2009) 1.09
Virus-based reporter systems for monitoring transcriptional activity of hypoxia-inducible factor 1. Gene (2005) 1.07
Regulation of gene expression by the hypoxia-inducible factors. Mol Interv (2002) 1.07
Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw (2008) 1.05
Assessing growth and response to therapy in murine tumor models. Methods Mol Med (2005) 1.03
Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Clin Cancer Res (2006) 1.01
Expression of transmembrane carbonic anhydrases, CAIX and CAXII, in human development. BMC Dev Biol (2009) 0.97
Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway. Oncol Rep (2012) 0.96
Bone morphogenetic protein 4 inhibits cell proliferation and induces apoptosis in glioma stem cells. Cancer Biother Radiopharm (2011) 0.95
A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells. Cell Death Differ (2012) 0.92
The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implications. ScientificWorldJournal (2011) 0.91
Brain tumour stem cells: implications for cancer therapy and regenerative medicine. Curr Stem Cell Res Ther (2008) 0.90
Molecular mechanisms of HIF-1alpha modulation induced by oxygen tension and BMP2 in glioblastoma derived cells. PLoS One (2009) 0.87
Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy. PLoS One (2011) 0.87
Glioblastoma: Part I. Current state of affairs. Mo Med (2011) 0.84
Isolation and expansion of regionally defined human glioblastoma cells in vitro. Curr Protoc Stem Cell Biol (2011) 0.81
MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients? J Neurooncol (2011) 0.81
The role of the anterior prefrontal cortex in human cognition. Nature (1999) 4.25
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 3.91
Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia (2005) 3.09
Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) Blood (1997) 2.40
Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology (2005) 1.90
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia (2009) 1.86
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia (2007) 1.79
Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors. Cancer Res (2000) 1.71
Metastatic oligodendrogliomas: a review of the literature and case report. Acta Neurochir (Wien) (2008) 1.68
Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia (2011) 1.67
Detection of membrane and intracellular antigens by flow cytometry following ORTHO PermeaFix fixation. Leukemia (1994) 1.54
Craniocerebral epidermoids and dermoids. A review of 44 cases. Acta Neurochir (Wien) (1989) 1.49
Outcome and lineage involvement in t(12;21) childhood acute lymphoblastic leukaemia. Br J Haematol (1997) 1.45
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol (2001) 1.41
Tumor outgrowth in peripheral blood mononuclear cell-injected SCID mice is not associated with early Epstein-Barr virus reactivation. Leukemia (2003) 1.40
Early and rapid diagnosis of CMV infection by nonradioactive in situ hybridization in pediatric kidney transplant recipients. Nephron (1992) 1.39
Decision-support and intelligent tutoring systems in medical education. Clin Invest Med (2000) 1.39
The calculating brain: an fMRI study. Neuropsychologia (2000) 1.32
Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia (2007) 1.27
Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia (2007) 1.25
Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene (1996) 1.25
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia (2009) 1.24
Recommendations for airway control and difficult airway management. Minerva Anestesiol (2005) 1.24
Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia (2004) 1.21
Helicobacter pylori virulence genes and host IL-1RN and IL-1beta genes interplay in favouring the development of peptic ulcer and intestinal metaplasia. Cytokine (2002) 1.20
Neural correlates of imaginal aggressive behavior assessed by positron emission tomography in healthy subjects. Am J Psychiatry (2000) 1.17
Diencephalic syndrome and disseminated juvenile pilocytic astrocytomas of the hypothalamic-optic chiasm region. Cancer (1997) 1.17
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia (2012) 1.16
Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia (2005) 1.16
N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. Tumori (1991) 1.16
Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring. Leukemia (2003) 1.16
Cortical localization of reading in normal children: an fMRI language study. Neurology (2001) 1.14
Intracranial hematomas following aneurysmal rupture: experience with 309 cases. Surg Neurol (1986) 1.13
MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J Clin Oncol (1997) 1.11
Treatment of cerebral arteriovenous malformations with a combination of preoperative embolization and surgery. Neurosurgery (1991) 1.09
CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia (2004) 1.09
Wnt activation promotes neuronal differentiation of glioblastoma. Cell Death Dis (2013) 1.08
Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol (1992) 1.08
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia (2008) 1.07
Intracranial aneurysms and subarachnoid hemorrhage in children and adolescents. Childs Nerv Syst (1986) 1.06
The relevance of anatomic and hemodynamic factors to a classification of cerebral arteriovenous malformations. Neurosurgery (1991) 1.06
Preoperative embolization of arteriovenous malformations with polylene threads: techniques with wing microcatheter and pathologic results. AJNR Am J Neuroradiol (1989) 1.06
Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. I. T lymphocyte requirement for B cell tumor generation. J Exp Med (1992) 1.06
Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements. Leukemia (2005) 1.04
DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. Leukemia (2009) 1.03
Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood (1998) 1.02
Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer (1996) 1.01
Spontaneous disappearance of intracranial arterio-venous malformations. Acta Neurochir (Wien) (1985) 0.98
Performance of personal inhalable aerosol samplers in very slowly moving air when facing the aerosol source. Ann Occup Hyg (2004) 0.97
Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol (1998) 0.96
Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in Italy. AIEOP/FONOP-TMO Group. Italian Association of Paediatric Haemato-Oncology. Bone Marrow Transplant (1998) 0.96
Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia: an MLL/AF4 identification. Leukemia (2003) 0.95
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia (2000) 0.94
An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood (1999) 0.94
Differential amygdala responses to winning and losing: a functional magnetic resonance imaging study in humans. Eur J Neurosci (2000) 0.94
Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. Br J Cancer (2013) 0.94
Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin Chem (1999) 0.94
Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia (2011) 0.93
Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma. Oncogene (1997) 0.93
Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br J Cancer (2012) 0.93
Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells. Leukemia (2011) 0.92
Macrocephaly, subarachnoid fluid collection, and glutaric aciduria type I. J Child Neurol (1996) 0.91
Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS). Leukemia (1999) 0.90
A mesenchymal chondrosarcoma of a child with the reciprocal translocation (11;22)(q24;q12). Cancer Genet Cytogenet (1993) 0.89
Cerebral cavernous malformations (cavernomas) in the pediatric age-group. Childs Nerv Syst (1991) 0.89
An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. Br J Cancer (2010) 0.89
ICER expression inhibits leukemia phenotype and controls tumor progression. Leukemia (2008) 0.88
Frequency of a mutated CCR-5 allele (delta32) among Italian healthy donors and individuals at risk of parenteral HIV infection. AIDS Res Hum Retroviruses (1999) 0.88
Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification. Leukemia (2000) 0.88
Rapid identification of viable retrovirus-transduced cells using the green fluorescent protein as a marker. Gene Ther (1997) 0.88
MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia (2011) 0.88
Stem cell factor suppresses apoptosis in neuroblastoma cell lines. Exp Hematol (1997) 0.88
Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias. Leukemia (1995) 0.88
Transient acute monoblastic leukemia with reciprocal (8;16)(p11;p13) translocation. Pediatr Hematol Oncol (1996) 0.88
A comparison between in vivo and ex vivo HR-MAS 1H MR spectra of a pediatric posterior fossa lesion. Int J Mol Med (2005) 0.87
Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene (1993) 0.87
Acute promyelocytic leukemia in children: experience of the Italian Pediatric Hematology and Oncology Group (AIEOP). Leukemia (1994) 0.87
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia. Leukemia (2013) 0.87
Spatial extinction on double asynchronous stimulation. Neuropsychologia (1997) 0.86
Expression of type I interferon receptor in solid tumors of childhood. Mod Pathol (1997) 0.86
PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy. Leukemia (2009) 0.86
The angiogenic switch: implications in the regulation of tumor dormancy. Curr Mol Med (2009) 0.85
Intracisternal schwannoma of the spinal accessory nerve presenting as a normal pressure hydrocephalus syndrome. Case report and review of the literature. Neurosurg Rev (1994) 0.85